title: Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein.
abstract: We measured the capacity of human plasma to induce cholesterol efflux from Fu5AH rat hepatoma cells in four groups of men with or without non-insulin-dependent diabetes mellitus (NIDDM) and coronary artery disease (CAD). Plasma from men with both NIDDM and CAD (n = 47) had the lowest efflux capacity (17.3 +/- 3.6%) whereas healthy control subjects with neither diabetes nor CAD (n = 25) had the highest capacity (19.8 +/- 3.4%). The groups with CAD but no diabetes (n = 44) and with NIDDM but no CAD (n = 35) had intermediate efflux values (18.5 +/- 3.8 and 18.5 +/- 3.9%, respectively). In a 2 x 2 factorial ANOVA, the differences were significant with respect to the presence of CAD (P = 0.038) and NIDDM (P = 0.041), with no interaction between the factors. The concentration of HDL particles containing apolipoprotein (apo) A-I but no apo A-II (LpA-I) was not related to efflux capacity in univariate or multivariate analyses. A multivariate regression analysis showed that when controlled for the presence of NIDDM and CAD, the concentration of particles containing both apo A-I and apo A-II (LpA-I:A-II) and plasma phospholipid transfer protein activity were both positively, independently, and significantly (P < 0.001) related to cholesterol efflux capacity.
authors.affiliation: Department of Medicine, Helsinki University Central Hospital, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Syvänne
authors.forename: G
authors.initials: G
authors.lastname: Castro
authors.forename: C
authors.initials: C
authors.lastname: Dengremont
authors.forename: C
authors.initials: C
authors.lastname: De Geitere
authors.forename: M
authors.initials: M
authors.lastname: Jauhiainen
authors.forename: C
authors.initials: C
authors.lastname: Ehnholm
authors.forename: S
authors.initials: S
authors.lastname: Michelagnoli
authors.forename: G
authors.initials: G
authors.lastname: Franceschini
authors.forename: J
authors.initials: J
authors.lastname: Kahri
authors.forename: M R
authors.initials: MR
authors.lastname: Taskinen
mesh_terms: D000368:Aged; D000818:Animals; D016632:Apolipoprotein A-I / Q000502:physiology*; D016633:Apolipoprotein A-II / Q000502:physiology*; D001692:Biological Transport; D002352:Carrier Proteins / Q000502:physiology*; D002784:Cholesterol / Q000378:metabolism*; D003327:Coronary Disease / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D006801:Humans; D015592:Immunoradiometric Assay; D008114:Liver Neoplasms, Experimental / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000502:physiology*; D008875:Middle Aged; D015999:Multivariate Analysis; D049294:Phospholipid Transfer Proteins; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D002352:Carrier Proteins; D008565:Membrane Proteins; D049294:Phospholipid Transfer Proteins; D002784:Cholesterol